Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection
Status:
ENROLLING_BY_INVITATION
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy\_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with Mycobacterium abscessus with goal to reduce infection burden and improve pulmonary disease
Phase:
PHASE1
Details
Lead Sponsor:
Vancouver Coastal Health
Treatments:
Amikacin bedaquiline Clofazimine Linezolid Trimethoprim, Sulfamethoxazole Drug Combination